Lucia F.
- Country
- Italy
- Department
- Oncologia Medica e dei Tumori Immuno- correlati
Research Overview
- A Phase 2, Randomized, Open-Label Study of Two Dose Levels of Vobramitamab Duocarmazine in Participants with Metastatic Castration-Resistant Prostate Cancer (TAMARACK)
- A Phase 3, Randomized, Double-blind Trial of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC) (KEYNOTE-641)
- A Phase 2 Multi-Cohort, Open-Label, Multi-Center Clinical Study Evaluating the Efficacy and Safety of Disitamab Vedotin (RC48-ADC) Alone and in Combination with Pembrolizumab in Subjects with Locally Advanced Unresectable or Metastatic Urothelial Carcinoma That Expresses HER2
Data & Insights
Has run more than one trial at 123 of 322 partner sites.
Specializations
Non‑Small Cell Lung Cancer
Focus on molecularly defined subgroups of advanced disease, integrating targeted agents and immunotherapies.
- ALK‑positive tumors
- EGFR‑mutated variants
- HER2‑mutated and HER2‑expressing cancers
- KRAS G12C driven cancers
- Advanced/metastatic stages
Clinical activity is explored in patients unsuitable for surgery or requiring systemic therapy.
Breast Cancer
Investigation of hormone‑receptor positive, HER2‑negative, HER2‑positive, and triple‑negative disease across early and metastatic settings.
- HR‑positive / HER2‑negative tumors
- HER2‑positive disease
- Triple‑negative breast cancer
- Adjuvant and neoadjuvant strategies
- Resistance after CDK4/6 inhibition
Therapeutic approaches include endocrine agents, HER2‑directed therapies, and novel antibody‑drug conjugates.
Gynecologic Oncology
Emphasis on high‑risk ovarian, fallopian tube, primary peritoneal, and endometrial malignancies, particularly in recurrent or platinum‑resistant contexts.
- High‑grade serous ovarian cancer
- BRCA‑wild‑type ovarian cohorts
- Advanced endometrial carcinoma
- Recurrent disease after standard therapy
- Targeted and immunologic combinations
Research integrates molecular selection with novel agents to improve outcomes in resistant disease.
Lymphoma
Broad activity across Hodgkin and non‑Hodgkin subtypes, including T‑cell and B‑cell origins, with attention to relapsed or refractory disease.
- Classical Hodgkin lymphoma
- Diffuse large B‑cell lymphoma
- Follicular lymphoma
- Peripheral T‑cell lymphoma
- Marginal zone lymphoma
Therapeutic strategies involve checkpoint inhibition, BTK inhibition, and antibody‑based regimens.
Renal Cell Carcinoma and Other Solid Tumors
Exploration of systemic options for renal, mesothelioma, sarcoma, urothelial, and melanoma cancers, focusing on metastatic disease.
- Metastatic renal cell carcinoma
- Malignant pleural mesothelioma
- Advanced sarcoma subtypes
- Urothelial carcinoma with HER2 expression
- Melanoma resistant to prior therapy
Investigation includes targeted kinase inhibitors, antibody‑drug conjugates, and combination immunotherapy.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.